Aimmune Therapeutics, Inc. (AIMT - Free Report) was a big mover last session, as the company saw its shares rise almost 9% on the day. The upside was driven by the announcement that Nestlé Health Science will make a $145.0 million equity investment in Aimmune for strategic collaboration to enable the successful development and commercialization of innovative food allergy therapies. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $16.26 to $17.18 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Aimmune Therapeutics currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
A better-ranked Bio-Medical/Gene stock is Anika Therapeutics Inc. (ANIK - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>